Advertisement

Digestive Diseases and Sciences

, Volume 49, Issue 11–12, pp 1853–1861 | Cite as

N-Acetylcysteine, a Novel Treatment for Helicobacter pylori Infection

  • Hien Quoc HuynhEmail author
  • Richard T. L. Couper
  • Cuong D. Tran
  • Lynette Moore
  • Richard Kelso
  • Ross N. Butler
Article

Abstract

N-Acetylcysteine (NAC), being both a mucolytic agent and a thiol-containing antioxidant, may affect the establishment and maintenance of H. pylori infection within the gastric mucus layer and mucosa. Agar and broth dilution susceptibility tests determined the MIC of H. pylori strain SSI to NAC. H. pylori load in SSI strain-infected C57BL mice was determined as colony forming units per gram of gastric tissue. Gastritis assessment was scored and gastric surface hydrophobicity was determined by contact angle measurement. MICs of NAC were 5 to 10 and 10 to 15 mg/ml using the agar dilution and broth dilution methods, respectively. NAC (120 mg per day for 14 days) reduced the H. pylori load in mice by almost 1 log compared with sham treatment. Pretreatment with NAC (40 mg/day) also significantly reduced the H. pylori load but did not prevent H. pylori colonization. Both H. pylori infection and NAC reduced the surface hydrophobicity of murine gastric mucosa. No significant differences were observed in the gastritis scores of H. felis- or H. pylori-infected mice receiving either NAC or sham treatments. This study demonstrates that NAC inhibits the growth of H. pylori in both agar and broth susceptibility tests and in H. pylori-infected mice. NAC did not alter the severity of H. pylori- or H. felis-induced gastritis.

Helicobacter pylori mucus N-acetylcysteine hydrophobicity treatment 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Passaro DJ, Chosy EJ, Parsonnet J: Helicobacter pylori: Consensus and controversy. Clin Infect Dis 35:298–304, 2002CrossRefPubMedGoogle Scholar
  2. 2.
    Nomura A, Stemmermann GN, Chyou PH, Perez-Perez GI, Blaser MJ: Helicobacter pylori infection and the risk for duodenal and gastric ulceration. Ann Intern Med 120:977–981, 1994CrossRefPubMedGoogle Scholar
  3. 3.
    Parsonnet J, Hansen S, Rodriguez L, Gelb AB, Warnke RA, Jellum E, Orentreich N, Vogelman JH, Friedman GD: Helicobacter pylori infection and gastric lymphoma. N Engl J Med 330:1267–1271, 1994CrossRefGoogle Scholar
  4. 4.
    Qasim A, O’Morain CA: Review article: Treatment of Helicobacter pylori infection and factors influencing eradication. Aliment Pharmacol Ther 16 (Suppl 1):24–30, 2002CrossRefPubMedGoogle Scholar
  5. 5.
    Mollison LC, Stingemore N, Wake RA, Cullen DJ, McGechie DB: Antibiotic resistance in Helicobacter pylori. Med J Aust 173:521–523, 2000PubMedGoogle Scholar
  6. 6.
    Scott D, Weeks D, Melchers K, Sachs G: The life and death of Helicobacter pylori. Gut 43 (Suppl 1):S56–S60, 1998CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Jarosz M, Dzieniszewski J, Dabrowska-Ufniarz E, Wartanowicz M, Ziemlanski S, Reed PI: Effects of high dose vitamin C treatment on Helicobacter pylori infection and total vitamin C concentration in gastric juice. Eur J Cancer Prev 7:449–454, 1998CrossRefPubMedGoogle Scholar
  8. 8.
    Goodman KJ, Correa P, Tengana Aux HJ, DeLany JP, Collazos T: Nutritional factors and Helicobacter pylori infection in Colombian children. J Pediatr Gastroenterol Nutr 25:507–515, 1997CrossRefPubMedGoogle Scholar
  9. 9.
    Ziment I: Acetylcysteine: A drug that is much more than a mucokinetic. Biomed Pharmacother 42:513–519, 1988PubMedGoogle Scholar
  10. 10.
    Misawa M and Imamura N: [In vitro evaluation of mucolytic activities of some expectorants using porcine gastric mucin]. Nippon Yakurigaku Zasshi 92:263–270, 1988CrossRefPubMedGoogle Scholar
  11. 11.
    Parry MF, Neu HC: Effect of N-acetylcysteine on antibiotic activity and bacterial growth in vitro. J Clin Microbiol 5:58–61, 1977PubMedPubMedCentralGoogle Scholar
  12. 12.
    Riise GC, Qvarfordt I, Larsson S, Eliasson V, Andersson BA: Inhibitory effect of N-acetylcysteine on adherence of Streptococcus pneumoniae and Haemophilus influenzae to human oropharyngeal epithelial cells in vitro. Respiration 67:552–558, 2000CrossRefGoogle Scholar
  13. 13.
    Stey C, Steurer J, Bachmann S, Medici TC, Tramer MR: The effect of oral N-acetylcysteine in chronic bronchitis: A quantitative systematic review. Eur Respir J 16:253–262, 2000CrossRefPubMedGoogle Scholar
  14. 14.
    Keays R, Harrison PM, Wendon JA, Forbes A, Gove C, Alexander GJ, Williams R: Intravenous acetylcysteine in paracetamol induced fulminant hepatic failure: A prospective controlled trial. BMJ 303:1026–1029, 1991; Ben-Ari Z, Vaknin H, Tur-Kaspa R: N-Acetylcysteine in acute hepatic failure (non-paracetamol-induced). Hepatogastroenterology 47:786–789, 2000CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Lee A, O’Rourke J, De Ungria MC, Robertson B, Daskalopoulos G, Dixon MF: A standardized mouse model of Helicobacter pylori infection: Introducing the Sydney strain. Gastroenterology 112:1386–1397, 1997CrossRefPubMedGoogle Scholar
  16. 16.
    Lee A, Fox JG, Otto G, Murphy J: A small animal model of human Helicobacter pylori active chronic gastritis. Gastroenterology 99:1315–1323, 1990CrossRefPubMedGoogle Scholar
  17. 17.
    Reina J, Alomar P: [Biochemical, physiological, and enzymatic study of 78 strains of Helicobacter (Campylobacter) pylori isolated from gastroduodenal biopsies]. Enferm Infecc Microbiol Clin 8:153–156, 1990PubMedGoogle Scholar
  18. 18.
    Court M, Robinson PA, Dixon MF, Crabtree JE: Gastric Helicobacter species infection in murine and gerbil models: Comparative analysis of effects of H. pylori and H. felis on gastric epithelial cell proliferation. J Infect Dis 186:1348–1352, 2002CrossRefPubMedGoogle Scholar
  19. 19.
    Stolte M, Meining A: The updated Sydney system: classification and grading of gastritis as the basis of diagnosis and treatment. Can J Gastroenterol 15:591–598, 2001CrossRefPubMedGoogle Scholar
  20. 20.
    Spychal RT, Marrero JM, Saverymuttu SH, Northfield TC: Measurement of the surface hydrophobicity of human gastrointestinal mucosa. Gastroenterology 97:104–111, 1989CrossRefPubMedGoogle Scholar
  21. 21.
    Day AS, Jones NL, Policova Z, Jennings HA, Yau EK, Shannon P, Neumann AW and Sherman PM: Characterization of virulence factors of mouse-adapted Helicobacter pylori strain SS1 and effects on gastric hydrophobicity. Dig Dis Sci 46:1943–1951, 2001 Hackelsberger A, Platzer U, Nilius M, Schultze V, Gunther T, Dominguez-Munoz JE, Malfertheiner P: Age and Helicobacter pylori decrease gastric mucosal surface hydrophobicity independently. Gut 43:465–469, 1998; Day AS, Jones NL, Policova Z, Jennings HA, Yau EK, Shannon P, Neumann AW and Sherman PM: Characterization of virulence factors of mouse-adapted Helicobacter pylori strain SS1 and effects on gastric hydrophobicity. Dig Dis Sci 46:1943–1951, 2001CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Zala G, Flury R, Wust J, Meyenberger C, Ammann R, Wirth HP: Omeprazole/amoxicillin: Improved eradication of Helicobacter pylori in smokers because of N-acetylcysteine. Schweiz Med Wochenschr 124:1391–1397, 1994PubMedGoogle Scholar
  23. 23.
    Olofsson AC, Hermansson M, Elwing H: N-Acetyl-L-cysteine affects growth, extracellular polysaccharide production, and bacterial biofilm formation on solid surfaces. Appl Environ Microbiol 69:4814–4822, 2003CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Perez-Giraldo C, Rodriguez-Benito A, Moran FJ, Hurtado C, Blanco MT, Gomez-Garcia AC: Influence of N-acetylcysteine on the formation of biofilm by Staphylococcus epidermidis. J Antimicrob Chemother 39:643–646, 1997CrossRefPubMedGoogle Scholar
  25. 25.
    Zheng CH, Ahmed K, Rikitomi N, Martinez G, Nagatake T: The effects of S-carboxymethylcysteine and N-acetylcysteine on the adherence of Moraxella catarrhalis to human pharyngeal epithelial cells. Microbiol Immunol 43:107–113, 1999CrossRefPubMedGoogle Scholar
  26. 26.
    An YH, Friedman RJ: Concise review of mechanisms of bacterial adhesion to biomaterial surfaces. J Biomed Mater Res 43:338–348, 1998CrossRefPubMedGoogle Scholar
  27. 27.
    Stark RM, Gerwig GJ, Pitman RS, Potts LF, Williams NA, Greenman J, Weinzweig IP, Hirst TR, Millar MR: Biofilm formation by Helicobacter pylori. Lett Appl Microbiol 28:121–126, 1999CrossRefPubMedGoogle Scholar
  28. 28.
    Hogan DL, Ainsworth MA, Isenberg JI: Review article: Gastroduodenal bicarbonate secretion. Aliment Pharmacol Ther 8:475–488, 1994CrossRefPubMedGoogle Scholar
  29. 29.
    Shimizu T, Akamatsu T, Sugiyama A, Ota H, Katsuyama T: Helicobacter pylori and the surface mucous gel layer of the human stomach. Helicobacter 1:207–218, 1996CrossRefPubMedGoogle Scholar
  30. 30.
    Slomiany BL, Liau YH, Lopez RA, Piotrowski J, Czajkowski A, Slomiany A: Effect of Helicobacter pylori lipopolysaccharide on the synthesis of sulfated gastric mucin. Biochem Int 27:687–697, 1992PubMedGoogle Scholar
  31. 31.
    Byrd JC, Yunker CK, Xu QS, Sternberg LR, Bresalier RS: Inhibition of gastric mucin synthesis by Helicobacter pylori. Gastroenterology 118:1072–1079, 2000CrossRefPubMedGoogle Scholar
  32. 32.
    Dial EJ, Hall LR, Serna H, Romero JJ, Fox JG, Lichtenberger LM: Antibiotic properties of bovine lactoferrin on Helicobacter pylori. Dig Dis Sci 43:2750–2756, 1998CrossRefPubMedGoogle Scholar
  33. 33.
    Drouin E: Helicobacter pylori: Novel therapies. Can J Gastroenterol 13:581–583, 1999CrossRefPubMedGoogle Scholar
  34. 34.
    Bell AE, Sellers LA, Allen A, Cunliffe WJ, Morris ER, Ross-Murphy SB: Properties of gastric and duodenal mucus: Effect of proteolysis, disulfide reduction, bile, acid, ethanol, and hypertonicity on mucus gel structure. Gastroenterology 88:269–280, 1985CrossRefPubMedGoogle Scholar
  35. 35.
    Goggin PM, Marrero JM, Spychal RT, Jackson PA, Corbishley CM, Northfield TC: Surface hydrophobicity of gastric mucosa in Helicobacter pylori infection: Effect of clearance and eradication. Gastroenterology 103:1486–1490, 1992CrossRefPubMedGoogle Scholar
  36. 36.
    Gotoh A, Akamatsu T, Shimizu T, Shimodaira K, Kaneko T, Kiyosawa K, Ishida K, lkeno T, Sugiyama A, Kawakami Y, Ota H, Katsuyama T: Additive effect of pronase on the efficacy of eradication therapy against Helicobacter pylori. Helicobacter 7:183–191, 2002CrossRefPubMedGoogle Scholar
  37. 37.
    Phull PS, Green CI, Jacyna MR: A radical view of the stomach: The role of oxygen-derived free radicals and anti-oxidants in gastroduodenal disease. Eur J Gastroenterol Hepatol 7:265–274, 1995PubMedGoogle Scholar
  38. 38.
    Li CQ, Pignatelli B, Ohshima H: Increased oxidative and nitrative stress in human stomach associated with cagA+ Helicobacter pylori infection and inflammation. Dig Dis Sci 46:836–844, 2001CrossRefPubMedGoogle Scholar
  39. 39.
    Kim H, Seo JY, Kim KH: Inhibition of lipid peroxidation, NF-kappaB activation and IL-8 production by rebamipide in Helicobacter pylori-stimulated gastric epithelial cells. Dig Dis Sci 45:621–628, 2000CrossRefPubMedGoogle Scholar
  40. 40.
    Obst B, Wagner S, Sewing KF, Beil W: Helicobacter pylori causes DNA damage in gastric epithelial cells. Carcinogenesis 21:1111–1115, 2000CrossRefPubMedGoogle Scholar
  41. 41.
    Khanzode SS, Khanzode SD, Dakhale GN: Serum and plasma concentration of oxidant and antioxidants in patients of Helicobacter pylori gastritis and its correlation with gastric cancer. Cancer Lett 195:27–31, 2003CrossRefPubMedGoogle Scholar
  42. 42.
    Pignatelli B, Bancel B, Plummer M, Toyokuni S, Patricot LM, Ohshima H: Helicobacter pylori eradication attenuates oxidative stress in human gastric mucosa. Am J Gastroenterol 96: 1758–1766, 2001CrossRefPubMedGoogle Scholar
  43. 43.
    Noguchi K, Kato K, Moriya T, Suzuki T, Saito M, Kikuchi T, Yang J, Imatani A, Sekine H, Ohara S, Toyota T, Shimosegawa T, Sasano H: Analysis of cell damage in Helicobacter pylori-associated gastritis. Pathol Int 52:110–118, 2002CrossRefPubMedGoogle Scholar
  44. 44.
    Zhang HM, Wakisaka N, Maeda O, Yamamoto T: Vitamin C inhibits the growth of a bacterial risk factor for gastric carcinoma: Helicobacter pylori. Cancer 80:1897–1903, 1997CrossRefPubMedGoogle Scholar
  45. 45.
    Wang X, Willen R, Wadstrom T: Astaxanthin-rich algal meal and vitamin C inhibit Helicobacter pylori infection in BALB/cA mice. Antimicrob Agents Chemother 44:2452–2457, 2000 27CrossRefPubMedPubMedCentralGoogle Scholar
  46. 46.
    Gressier B, Cabanis A, Lebegue S, Brunet C, Dine T, Luyckx M, Cazin M, Cazin JC: Decrease of hypochlorous acid and hydroxyl radical generated by stimulated human neutrophils: Comparison in vitro of some thiol-containing drugs. Methods Find Exp Clin Pharmacol 16:9–13, 1994PubMedGoogle Scholar
  47. 47.
    Chu SH, Kim H, Seo JY, Lim JW, Mukaida N, Kim KH: Role of NF-kappaB and AP-l on Helicobater pylori-induced IL-8 expression in AGS cells. Dig Dis Sci 48:257–265, 2003CrossRefPubMedGoogle Scholar
  48. 48.
    Hayakawa M, Miyashita H, Sakamoto I, Kitagawa M, Tanaka H, Yasuda H, Karin M, Kikugawa K: Evidence that reactive oxygen species do not mediate NF-kappaB activation. EMBO J 22:3356–3366, 2003CrossRefPubMedPubMedCentralGoogle Scholar
  49. 49.
    Lee A: Animal models of gastroduodenal ulcer disease. Bailliere’s Best Pract Res Clin Gastroenterol 14:75–96, 2000CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, Inc. 2004

Authors and Affiliations

  • Hien Quoc Huynh
    • 1
    • 5
    Email author
  • Richard T. L. Couper
    • 1
    • 2
  • Cuong D. Tran
    • 1
  • Lynette Moore
    • 3
  • Richard Kelso
    • 4
  • Ross N. Butler
    • 1
  1. 1.Gastroenterology UnitWomen’s Children’s HospitalNorth Adelaide
  2. 2.University Department of PediatricWomen’s Children’s HospitalNorth Adelaide
  3. 3.Department of PathologyWomen’s Children’s HospitalNorth Adelaide
  4. 4.Department of Mechanical EngineeringUniversity of AdelaideNorth Adelaide
  5. 5.Department of PediatricsUniversity of AlbertaEdmontonCanada

Personalised recommendations